Loading…
Develops CAR-T cell therapies for blood cancers; co-markets Carvykti for multiple myeloma with Johnson & Johnson.
Develops CAR-T cell therapies for blood cancers; co-markets Carvykti for multiple myeloma with Johnson & Johnson.
Janssen, Johnson & Johnson's drug unit, sells Carvykti, and the two companies share costs and profits, so Legend's income arrives as collaboration payments rather than direct drug sales. Each dose is made from the individual patient's own cells, so manufacturing capacity limits how many patients can be treated.
Moat: narrow (IP / patents, process know-how, regulatory licence). Complex CAR-T manufacturing and J&J's global commercial reach are hard to replicate quickly.
Headquarters: Somerset, New Jersey, US · Founded: 2014 · Employees: 2,900
Size Legend Biotech Corp. Sponsored ADR (LEGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.53B, the 1254th largest of 3,117 United States companies the cockpit tracks. Shares closed at $23.40 on 6 Nov 2026.
Performance Over six months the shares fell 16.8%, against +3.3% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 59.6% over the last twelve months (peer median +13.0%); the operating margin is -4.1% (peer median 18.1%).
Valuation It trades at 64.5× forward earnings against a peer median of 31.8× (most expensive of 17).
Capital Return on invested capital runs 15.1 points below its cost of capital (7.5% WACC).
Short interest Short interest is 7.2% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.27B | $1.03B | $628M | $285M | $117M |
| Revenue growth | — | +64% | +120% | +144% | — |
| Gross profit | $676M | $593M | $369M | $120M | $33.2M |
| EBITDA | -$6.97M | -$108M | -$286M | -$421M | -$439M |
| Net income | -$91.9M | -$298M | -$177M | -$518M | -$446M |
| Free cash flow | -$264M | -$168M | -$210M | -$503M | -$235M |
| Capital expenditure | $81.2M | $67.6M | $69.0M | $121M | $37.0M |
| Total debt | $278M | $414M | $351M | $329M | $285M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Legend Biotech Corp. Sponsored ADR LEGN | $4.53B | -17% | +60% | -4% | 64.5× | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 9.7× | -12.9% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 19.3× | -2.9% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 11.3× | -2.2% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | $341M | -18% | +288% | -211% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LEGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.1% | +1.7% | 2nd highest of 20 |
| 6-month return | -16.8% | +3.3% | 5th lowest of 20 |
| Distance from 52-week high | -37.6% | -31.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +59.6% | +13.0% | 3rd highest of 19 |
| Operating margin | -4.1% | 18.1% | 2nd lowest of 19 |
| Forward P/E | 64.5× | 31.8× | most expensive of 17 |
| ROIC minus cost of capital | -15.1 pp | +7.3 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.56B | -23% | +6% | 3% | 7.3× | 0.7% | +4.0% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | n/a | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% | +9.7% |